Andere Sprachen Cullinan Therapeutics, Inc.

Aktien

A2QL3C

US2300311063

CGEM

Verzögert Nasdaq Andere Börsenplätze 22:00:00 18.06.2024			% 5 Tage	% 1. Jan.
16.81 ^USD	-11.62%		-27.70%	+64.97%

02.06.	Transcript : Cullinan Therapeutics, Inc. - Special Call
01.06.	Cullinan Therapeutics, Inc. gibt positive erste Daten aus der zulassungsrelevanten Phase-2b-Studie Rezil1 mit Zipalertinib bekannt	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib	01.06.
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib	01.06.
Cullinan Therapeutics, Inc. Announces Positive Initial Data from Pivotal Phase 2b Rezil1 Study of Zipalertinib	01.06.
Cullinan Therapeutics : Full Pipeline Overview	01.06.
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit	24.05.
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024	23.05.
Cullinan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15.05.
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results	15.05.
Cullinan Therapeutics, Inc. Announces Board Changes	15.05.
Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing	09.05.
Cullinan Therapeutics, Inc. announced that it has received $280.000024 million in funding from a group of investors	30.04.
Cullinan Therapeutics Appoints Mary Kay Fenton as CFO	29.04.
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer	29.04.
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer	29.04.
Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer	29.04.
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024	24.04.
Cullinan Oncology : Therapeutics Corporate Update	16.04.
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases	16.04.
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases	16.04.
Cullinan Oncology, Inc. Announces Important Updates About Its Plan to Expand into Autoimmune Diseases, the Scientific Rationale for Developing CLN-978 in Autoimmune Diseases	16.04.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cullinan Therapeutics, Inc.

Aktien

A2QL3C

US2300311063

CGEM

Andere Sprachen

Filter